by Raynovich Rod | Oct 31, 2016 | Biopharmaceuticals
Biotech Meltdown: Numbers Don’t Mean Much Until We See New Product Growth We are almost through the earnings season and despite good results most biotech stocks tanked again today.The reason you know well by now-expectations for earnings and top line growth have...
by Raynovich Rod | Oct 26, 2016 | Biopharmaceuticals, Macro
Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson...
by Raynovich Rod | Oct 21, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
CLIA Labs Offer Liquid Biopsy Tests for Cancer and Precision Medicine We attended presentations from two emerging companies developing molecular diagnostics platforms focused in cancer.Their mission is to develop cost-effective, non-invasive diagnostic assays and...
by Raynovich Rod | Oct 20, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Microbiomes: A New Paradigm for Drug Discovery? Focus: Drugs From Gut Bacteria You may have read a few articles about the impact of the microbiomes and their impact on diets, digestion and nutrition but now there is the potential of discovering new therapies from...
by Raynovich Rod | Oct 17, 2016 | Biopharmaceuticals
BIO Investor Forum 2016 We will be attending the BIO Investor Forum beginning Tuesday October 18 for two days. Last year the meeting was excellent for coverage of small cap biotech companies and important issues and trends in the life science industry. Over 100...
by Raynovich Rod | Oct 12, 2016 | Biopharmaceuticals
Update-1… 10/14…2:30p EDT Ariad Pharmaceuticals (ARIA) Drops 8.25% to $12 on Senator Bernie Sanders Criticism of Drug Pricing; Sanders was also on Bill Maher (HBO) XBI down 2.25% just below support of $60 Update-2… 10/15…Biotech Blues-Tough...
by Raynovich Rod | Oct 11, 2016 | Clinical Diagnostics and Tools
Update-1 Biotechs Sinking Again …IBB down 2.48%, ILMN down another 2% Related sequencing stocks: FMI down 1.75%, PACB flat at $8.40 Illumina (ILMN) Shares Crash on Revenue Miss Illumina (ILMN) shares crashed 25% to $139, after a warning on third quarter sales ....
by Raynovich Rod | Oct 5, 2016 | Biopharmaceuticals
Green Tape Today Shows Resilience– 10/10/16 ESMO Cancer Congress 4%+ Up movers: AGIO ARIA BLUE CLVS LGND PBYI TSRO etc. XBI up 2.39% More Bad Clinical News for Biotech:ALNY,CLVS The XBI lost 3.2% for the week to $64.15 taking a hit from Alnylam (ALNY) downdraft...